Former Head of Research & Development · Larimar Therapeutics, Inc. (LRMR)

Priya Singhal

FY2019 is the first fiscal year CompBrief holds for Priya Singhal as a named executive officer of Larimar Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,398,665

Salary $360,852Stock awards $0Bonus $174,000

2nd of 3 named executive officers at Larimar Therapeutics by FY2019 total.

3 named officers on file for Larimar Therapeutics, FY2019

Priya Singhal’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Larimar Therapeutics’s whole pay program stands against its peers

  • Larimar Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LRMR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed August 19, 2020 (DEF 14A).

Free

Get Priya Singhal’s full pay file as a PDF — free

More than this page: up to 10 years of Priya’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Priya Singhal compensation by year

Larimar Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Larimar Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$360,852
Bonus$174,000
Stock awards$0
Option awards$855,413
Non-equity incentive$0
Pension and deferred compensation$0
All other$8,400
Total$1,398,665

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Larimar Therapeutics, Inc. DEF 14A filed August 19, 2020, accession 0001193125-20-224087, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Larimar Therapeutics, Inc. filed document, accession 0001193125-20-224087. Every figure is read from that document and cited to the page and table it appears in. Filed August 19, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option31,250—$34.68

Per the Outstanding Equity Awards at Fiscal Year-End table in Larimar Therapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Larimar Therapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Jeffrey HatfieldFormer Chief Executive Officer$3,236,560
Priya Singhal · this pageFormer Head of Research & Development$1,398,665
Brian McVeighFormer Chief Business Officer$1,091,509

The full Larimar Therapeutics compensation record

free company brief

This page is one person within Larimar Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Larimar Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Priya Singhal's compensation dossier · One-time report. No refunds.